TLDR GE stock dropped 3.7% to $327.13 on Thursday, hitting an intraday low of $320.79 The pullback comes after a ~73% run-up, with profit-taking and broader marketTLDR GE stock dropped 3.7% to $327.13 on Thursday, hitting an intraday low of $320.79 The pullback comes after a ~73% run-up, with profit-taking and broader market

GE Aerospace (GE) Stock Pulls Back 4% as Investors Lock In Gains

2026/03/06 21:58
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

TLDR

  • GE stock dropped 3.7% to $327.13 on Thursday, hitting an intraday low of $320.79
  • The pullback comes after a ~73% run-up, with profit-taking and broader market weakness cited as key drivers
  • Q4 earnings beat expectations with EPS of $1.57 vs. $1.43 estimate; revenue came in at $11.90B vs. $11.27B expected
  • FY-2026 guidance raised to 7.100–7.400 EPS, and the quarterly dividend was lifted from $0.36 to $0.47
  • Analyst consensus sits at “Moderate Buy” with an average price target of $331.12; Goldman Sachs targets $350

GE Aerospace stock slid 3.7% on Thursday, closing at $327.13 after touching an intraday low of $320.79. The prior close was $339.81. Trading volume came in around 4.75 million — about 16% below the daily average.


GE Stock Card
GE Aerospace, GE

The move lower wasn’t tied to any company-specific bad news. Analysts and market watchers pointed to two familiar culprits: profit-taking after a strong run and a weaker broader market backdrop.

GE has climbed roughly 73% over the past year, pulling it close to its 52-week high. At current prices, it trades at a price-to-earnings ratio of around 40, which leaves it exposed when sentiment turns.

After-hours futures were sliding and oil prices were rising that day — a combination that tends to put pressure on richly valued, high-beta names like GE.

On the fundamentals side, the story remains solid. GE reported Q4 earnings of $1.57 per share, beating the consensus estimate of $1.43. Revenue came in at $11.90 billion, above the $11.27 billion expected, and up 17.6% year-over-year.

The company raised its full-year 2026 guidance to a range of 7.100–7.400 EPS. Sell-side analysts, on average, are modeling $5.40 EPS for the current fiscal year.

GE also bumped its quarterly dividend to $0.47 per share — up from $0.36 — payable April 27 to holders of record as of March 9.

Analyst Ratings

The analyst community remains broadly supportive. JPMorgan raised its price target from $325 to $335 with an “overweight” rating in January. Goldman Sachs lifted its target from $338 to $350 with a “buy.” Susquehanna maintained a “positive” rating with a $380 target.

Not everyone is on board. BNP Paribas Exane cut its target to $290 and rates the stock “underperform.” Wall Street Zen moved from “buy” to “hold” in late February.

The overall consensus sits at “Moderate Buy” with an average price target of $331.12 — only slightly above where the stock is currently trading.

Business Fundamentals

Under the hood, GE’s engine services business is the main engine of growth — no pun intended. Commercial Engines & Services revenue grew 24% in 2025, with the services segment growing even faster at 26%.

The company has a backlog of approximately $190 billion, giving it strong multi-year revenue visibility. Its installed base covers more than 45,000 commercial engines, the foundation for recurring maintenance and service revenue under long-term agreements.

The book-to-bill ratio hit 2.3x in the most recent quarter, meaning it’s booking new business at more than twice the rate it’s delivering it.

On the insider front, VP Robert M. Giglietti sold 3,035 shares on January 30 at $305.51. SVP Amy L. Gowder sold 4,000 shares on February 2 at $305.73. Insiders have collectively sold 37,398 shares worth roughly $11.46 million over the past quarter.

The stock’s 50-day moving average sits at $319.29, and the 200-day is at $303.08, both well below current price levels.

The post GE Aerospace (GE) Stock Pulls Back 4% as Investors Lock In Gains appeared first on CoinCentral.

Market Opportunity
4 Logo
4 Price(4)
$0.008039
$0.008039$0.008039
-1.78%
USD
4 (4) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09